Cannabis Science (CBIS) 10-Q 4 Jun 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Jun. 02, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'CANNABIS SCIENCE, INC.	'
Entity Central Index Key	'0001024626	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	844,323,906

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$866,428	$943
Accounts receivable, related party	697	697
Prepaid expenses and deposits	3,564	'
Advances receivable, related party	76,315	76,315
Marketable securities (Note 3)	539,250	225,000
Total current assets	1,486,254	302,955
Computer and equipment, net of accumulated depreciation of $12,825 and $12,200 (Note 8)	891	1,516
Goodwill (Note 1)	66,274	66,274
Intangibles, net of accumulated amortization (Note 9)	185,566	206,709
TOTAL ASSETS	1,738,985	577,454
Current Liabilities	'	'
Accounts payable	135,582	165,839
Accrued expenses, primarily management fees (Note 5)	1,483,413	1,336,904
Advances from related parties (Note 5)	191,344	191,344
Management bonuses	300,000	300,000
Notes payable to stockholders (Note 6)	2,086,186	2,102,186
Total current liabilities and total liabilities	4,196,525	4,096,273
Stockholders' Deficit	'	'
Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at March 31, 2013 and 666,666 at December 31, 2013	1,000	1,000
Common stock value	836,784	770,524
Prepaid consulting	-3,394,414	-3,553,296
Additional paid-in capital	98,434,879	91,771,495
Accumulated deficit	-98,335,789	-92,508,542
Total stockholders' deficit	-2,555,434	-3,518,819
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,738,985	577,454
Common Class A [Member]	'	'
Stockholders' Deficit	'	'
Common stock value	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Computer and Equipment, net of accumulated depreciation	$12,825	$12,200	'
Preferred stock, par value	$0.00	$0.00	'
Preferred stock, shares authorized	1,000,000	1,000,000	'
Preferred stock, shares issued	1,000,000	666,666	'
Preferred stock, shares outstanding	1,000,000	666,666	'
Common stock, par value	$0.00	$0.00	'
Common stock, shares authorized	850,000,000	850,000,000	'
Common stock, shares issued	836,783,906	770,523,906	663,790,573
Common stock, shares outstanding	836,783,906	770,523,906	'
Common Class A [Member]	'	'	'
Common stock, par value	$0.00	$0.00	'
Common stock, shares authorized	100,000,000	100,000,000	'
Common stock, shares issued	0	0	'
Common stock, shares outstanding	0	0	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenue	$1,031	$1,604
Operating Expenses	'	'
Investor relations	'	214
Professional fees	15,215	24,980
Technology license royalties	'	'
Impairment of oil and gas well lease	'	'
Impairment loss on goodwill	'	'
Net loss on disposal of assets	'	8,896
Inventory write-down	'	'
Depreciation and Amortization	21,768	42,958
General and administrative	3,058,091	760,623
Total operating expenses	3,095,074	837,671
Net Operating Profit (Loss)	-3,094,043	-836,067
Other income (expense)	'	'
Interest income, net	'	'
Interest expense, net	-60	-277
Debt extension expense	-833,000	'
Warrant expense	-97,894	'
Gain on sale of assets	'	262,250
Loss on settlement of liabilities	-2,116,500	-1,092,150
Gain on derecognized liabilities	'	37,458
Unrealized gain (loss) on marketable common stock	314,250	-149,750
Beneficial conversion feature	'	'
Net Income (Loss) Before Income Taxes	-5,729,353	-1,778,536
Net Loss	($5,729,353)	($1,778,536)
- Basic and diluted	($0.01)	$0
Weighted average number of common shares outstanding	833,862,795	676,573,906

Consolidated_Statement_Of_Stoc

Consolidated Statement Of Stockholders Equity (Deficit) (USD $)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Prepaid Consulting	Accumulated Deficit
Balance Amount at Dec. 31, 2011	($2,230,401)	$305,421	$1,000	$68,379,003	($379,156)	($70,536,669)
Common stock issued for services, Amount	1,147,425	171,670	'	5,965,555	-4,989,800	'
Common stock issued for services, Shares	'	171,669,999	'	'	'	'
Common stock issued for debt settlements, Amount	10,843,800	155,700	'	10,688,100	'	'
Common stock issued for debt settlements, Shares	'	155,700,000	'	'	'	'
Common stock issued for assets and acquisitions, Amount	773,430	22,750	'	750,680	'	'
Common stock issued for assets and acquisitions, Shares	'	22,750,000	'	'	'	'
Common stock issued in connection with joint ventures, Amount	338,800	7,000	'	331,800	'	'
Common stock issued in connection with joint ventures, Shares	'	7,000,000	'	'	'	'
Common stock pending issuance for services, Amount	441,000	7,000	'	434,000	'	'
Common stock pending issuance for services, Shares	'	7,000,000	'	'	'	'
Common stock pending cancellation for services, Amount	'	-750	'	750	'	'
Common stock pending cancellation for services, Shares	'	-750,000	'	'	'	'
Common stock pending cancellation for acquisition, Amount	'	-5,000	'	5,000	'	'
Common stock pending cancellation for acquisition, Shares	'	-5,000,000	'	'	'	'
Amortization of shares issued for services	2,504,886	'	'	'	2,504,886	'
Forfeiture of Series A Preferred stock, Amount	-333	'	-333	'	'	'
Forfeiture of Series A Preferred stock, Shares	'	'	-333,333	'	'	'
Stockholder gift to settle liability	50,000	'	'	50,000	'	'
Net Loss	-16,037,572	'	'	'	'	-16,037,572
Balance Amount at Dec. 31, 2012	-2,168,965	663,791	667	86,604,888	-2,864,070	-86,574,241
Common stock issued for services, Amount	1,009,630	57,900	'	2,314,621	-1,362,891	'
Common stock issued for services, Shares	'	57,900,000	'	'	'	'
Common stock issued for debt, Amount	2,376,150	48,000	'	2,328,150	'	'
Common stock issued for debt, Shares	'	48,000,000	'	'	'	'
Common stock issued for private placement, Amount	25,000	833	'	24,167	'	'
Common stock issued for private placement, Shares	'	833,333	'	'	'	'
Preferred stock issued for services, Amount	'	'	333	499,669	-500,002	'
Preferred stock issued for services, Shares	'	'	333,334	'	'	'
Amortization of shares issued for services	1,173,667	'	'	'	1,173,667	'
Net Loss	-5,934,301	'	'	'	'	-5,934,301
Balance Amount at Dec. 31, 2013	-3,518,819	770,524	1,000	91,771,495	-3,553,296	-92,508,542
Common stock issued for services, Amount	2,871,632	28,000	'	2,684,750	-283,750	'
Common stock issued for services, Shares	'	28,000,000	'	'	'	'
Common stock issued for debt, Amount	2,146,000	29,500	'	2,116,500	'	'
Common stock issued for debt, Shares	'	29,500,000	'	'	'	'
Common stock issued for extension of debt	833,000	5,000	'	828,000	'	'
Common stock issued for debt extension, Shares	'	5,000,000	'	'	'	'
Common stock issued for private placement, Amount	940,000	3,760	'	936,240	'	'
Common stock issued for private placement, Shares	'	3,760,000	'	'	'	'
Warrant expense	97,894	'	'	97,894	'	'
Amortization of shares issued for services	2,871,632	'	'	'	442,632	'
Net Loss	-5,729,353	'	'	'	'	-5,827,247
Balance Amount at Mar. 31, 2014	($2,555,434)	$836,784	$1,000	$98,434,879	($3,394,414)	($98,335,789)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($5,729,353)	($1,778,536)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	625	1,558
Amortization	21,143	41,400
Stock issued for services	2,871,632	677,217
Stock issued for the extension of debt	833,000	'
Gain on joint ventures	'	-262,250
Gain on marketable securities	-314,250	'
Loss on marketable securities	'	149,750
Loss on settlement of debt	2,116,500	1,092,150
Loss on disposal of assets	'	8,896
Changes in operating assets and liabilities:	'	'
Accounts receivable	'	'
Accounts receivable, related parties	'	25,000
Prepaid expenses and deposits	-3,564	-3,093
Accounts payable	-16,757	-228
Accrued expenses, including management fees	146,509	-87,871
NET CASH (USED) IN OPERATING ACTIVITIES	-74,515	-136,007
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Loans receivable, related parties	'	10,663
Advances receivable, related parties	'	-14,155
CASH FLOWS USED IN INVESTING ACTIVITIES	'	-3,492
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Repayments on advances from related parties	'	-1,000
Proceeds from notes payable-stockholders	'	98,000
Proceeds on advances from related parties	'	27,400
Proceeds from sale of common stock	940,000	'
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	940,000	124,400
NET INCREASE (DECREASE) IN CASH	865,485	-15,099
CASH, BEGINNING OF PERIOD	943	23,560
CASH, END OF PERIOD	866,428	8,461
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'
Common stock issued for services	2,871,632	677,217
Common stock issued for settlement of debt	2,146,000	1,092,150
Common stock issued for extension of debt	833,000	'
Debt converted into common stock	29,500	13,500
Marketable securities acquired through sale of JVs	'	262,250
Accounts payable and expenses paid through note payable, stockholder	13,500	20,000
Accounts payable paid by related parties	'	10,000
Intangibles, CCI allocated to goodwill	'	22,000
Intangibles, CCI allocated to intangibles	'	$125,000

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  On April 7, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.
	On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC: CBIS.
	Cannabis Science, Inc. is at the forefront of medical marijuana research and development.  The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.  In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
	The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10th and May 6th, 2013, respectively, to pursue business opportunities in Europe and worldwide.  There are currently no active operations in the subsidiaries.
	On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders."  The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.
	B.  Basis of Presentation
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP").  These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2013 audited financial statements of Cannabis Science, Inc. (the “Company”).  All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended March 31, 2014 and 2013.  It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2013 included in our Form 10-K, filed with the Securities Exchange Commission on April 23, 2013. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that can be expected for the year ending December 31, 2014.
	The operating results of GGECO University, Inc. (“GGECO”), acquired on February 9, 2012, for the period February 10, 2012 through December 31, 2013 were consolidated with the consolidated financial statements of the Company for the year ended December 31, 2013.  The s-type corporation of GGECO was dissolved in 2012 and all operations combined into the Company’s.  An independent valuation firm determined the intangibles acquired in GGECO to be $192,119 consisting of $150,000 for educational materials, $20,000 for the trade name, and $22,119 for the workforce.  The total purchase price of $450,132, including acquired net liabilities, audit and valuation costs was recorded.  A total of $44,274 in unimpaired goodwill remains at March 31, 2014.
	The operating results of Cannabis Consulting, Inc. (“CCI”), acquired on March 21, 2012, for the period March 21, 2012 through December 31, 2013 and January 1, 2014 through March 31, 2014 were consolidated with the consolidated financial statements of the Company for the three months ended March 31, 2014.  The s-type corporation of CCI was dissolved in 2012 and all operations combined into the Company’s.  The Company has allocated $125,000 of the purchase price to intangibles based on an internal valuation in addition to $22,000 of goodwill.  No impairment in the fair market value of CCI was determined at March 31, 2014.
	On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations.  No business or operating activities have commenced in the subsidiaries as of March 31, 2014.
	C.  Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
	D.  Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share.  Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.  For the three months ended March 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
	E.  Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
	F. Long-Lived Assets & Impairment on Oil Lease Investments
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used.  ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts.  In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets.  Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
	G. Inventory
	Inventories are stated at the lower of cost or market, using the average cost method. Cost includes materials related to the purchase and production of inventories. We regularly review inventory quantities on hand, future purchase commitments with our suppliers, and the estimated utility of our inventory. If our review indicates a reduction in utility below carrying value, we reduce our inventory to a new cost basis through a charge to cost of revenue.
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments.  The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4).  The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments.  None of these instruments are held for trading purposes.
	I. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. The Company did not identify any impairment on its outstanding goodwill from its most recent testing, which was performed as of October 1, 2013. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as customer lists, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight line method over estimated useful lives of five years.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired.  If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action.  If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
	The Company did not record an impairment loss on goodwill for the quarter ended March 31, 2014 and did not record an impairment loss on goodwill for 2013 that was included in operating expenses and resulting net operating loss.
	J. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
	K. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards.  Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards.  A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns
	In February 2009, the Company filed appropriate federal tax returns for the years ending December 31, 2003 through 2007 and may be subject to failure to file penalties.  For the years ending December 31, 2008 through December 31, 2013, the Company has not filed any federal tax returns.  The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position.  No provisions have been made in the financial statements for such penalties, if any.
	The Company is working with its accountants to prepare and file overdue federal tax returns for 2008 through 2013, which are anticipated to be completed and filed by the end of fiscal 2014.
	L. Marketable Securities
	Under ASC Topic 210; Rule 5-02.2, ‘‘Marketable Securities’’, the Company is required to measure all marketable securities at their carrying value while recognizing unrealized gains and losses as of the reporting date.
	M. Stock-Based Compensation
	Under  ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations.  The Company has adopted ASC Topic 718 (SFAS 123R) as of January 1, 2006 and recognizes stock-based compensation expense using the modified prospective method.
	N.  Revenue Recognition
	Revenue is recognized at the time the educational materials or online seminars are provided and billed to the customer and collection of such fee is reasonably assured.  License fees and joint-venture profit sharing when evidenced by executed agreements, and other fees are recognized when earned and collection is reasonably assured.
	O.  Development Stage Enterprise
	The Company is no longer in the development stage.  The Company has filed patents and is actively working on formulations for cannabinoid-based drug development, filing INDs, and commencing drug trials for FDA approved medicine.  The Company’s businesses of GGECO and CCI acquired during 2012 are continuing and the Company’s other activities under license agreements with Apothecary has completed over a year of active business and development with expanding operations along with associated business. The Company continues to work to prosecute patents and develop its two key drugs, namely CS-TATI-1 targeting both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies and CS-S/BCC-1 targeting basal and squamous cell carcinomas, along with its cannabinol (CBN) patent. In addition, the Company is working to progress licensing activity with Apothecary along with MOU activity with Prescription Vending Machines, Inc., a wholly-owned subsidiary of Medbox, Inc.
	P. Recent Accounting Pronouncements
	During the three months ended March 31, 2014 and through June 2, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company.  Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
	Q. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Going_Concern

Going Concern	3 Months Ended
	Mar. 31, 2014
Going Concern [Abstract]	'
GOING CONCERN	'
	2.  GOING CONCERN
	The accompanying consolidated financial statementshave been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern.  The Company reported an accumulated deficit of $98,335,789 and had a stockholders’ deficit of $2,457,540 at March 31, 2014.
	In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital.  At March 31, 2014, the Company had insufficient operating revenues and cash flow to meet its financial obligations.  There can be no assurance that management will be successful in implementing its plans.  The consolidated financial statementsdo not include any adjustments that might result from the outcome of this uncertainty.
	The Company raised $940,000 in the three months ended March 31, 2014.  Notwithstanding, we anticipate that we will have to raise additional capital to fund research and development and operations over the next 12 months.  To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities.  There are no  commitments  or arrangements  for  other  offerings  in  place,  no  guaranties  that  any  such financings would be forthcoming,  or as to the terms of any such financings.  Any future financing may involve substantial dilution to existing investors.  We had been relying on our common stock to pay third parties for services which has resulted substantial dilution to existing investors

Marketable_Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2014
Marketable Securities [Abstract]	'
MARKETABLE SECURITIES	'
	3.  MARKETABLE SECURITIES
	See Note 5 for transaction details on 7,500,000 common shares in the Endocan Corporation (OTC: ENDO) with a fair market value of $539,250 held by the Company at March 31, 2014.

Fair_Value_Measurements_and_Di

Fair Value Measurements and Disclosures	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements and Disclosures [Abstract]	'
Fair Value Measurements and Disclosures	'
	4.  FAIR VALUE MEASUREMENTS AND DISCLOSURES
	ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
	Level 1
	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities that the Company can access at the measurement date.
	Level 2
	Inputs to the valuation methodology are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
	Level 3
	Inputs to the valuation methodology are unobservable inputs for the asset of liability.
	The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
	Following is a description of the valuation methodologies used for the Company’s liabilities measured at fair value.  There have been no changes in the methodologies used at March 31, 2014.
	Investment in marketable securities: Trading securities valued at the closing price of ENDO shares held by the Company at period end.
	Intangibles from GGECO and CCI acquisitions:  Valued at replacement cost.  The replacement cost is determined as the cost of replacing the asset with a modern unit of the near equivalent utility.
	The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.  The following tables set forth by level, within the fair value hierarchy, the Company’s liabilities at fair value as of March 31, 2014.
	31-Dec-13
		Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	225,000	$	-	$	-	$	225,000
	Intangibles from acquisitions, GGECO and CCI net of accumulated amortization		-		-		237,480		237,480
	Total assets as of December 31, 2013	$	225,000	$	-	$	237,480	$	462,480
	31-Mar-14
		Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	204,000	$	-	$	-	$	204,000
	Intangibles from GGECO and CCI acquisitions, net of accumulated amortization		-		-		237,480		237,480
	Total assets as of March 31, 2014	$	204,000	$	-	$	237,480	$	441,480

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	5.  RELATED PARTY TRANSACTIONS
	At March 31, 2014, a total of $191,344 (December 31, 2013: $191,344) in loans payable was due to Bogat Family Trust, Raymond Dabney the Company’s Managing Consultant as trustee, and $0 to Raymond Dabney (December 31, 2013: $6,166).  The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment.  Raymond Dabney also performs management services to the Company under a Management Consulting Agreement signed on February 9, 2012.
	At March 31, 2014, the Company held 7,500,000 common shares in the Endocan Corporation (formerly X-Change Corporation) (OTC: ENDO) (“Endocan”) representing approximately 8.6% of the issued and outstanding shares of X-Change, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0.03 on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of $262,250 or $0.1049 per share on February 8, 2013.  The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the dupetit Natural Products GmbH joint-venture operating agreement to Endocan under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Endocan under an Asset Purchase Agreement.  The value of the shares at March 31, 2014 was determined to be $0.0719 per share or $539,250 with the Company recording an unrealized gain of $314,250 for the three months ended March 31, 2014.  Dr. Dorothy Bray, CEO and director is also President and director of Endocan, Robert Kane, CFO and director is also the CFO and a director of Endocan.  Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Endocan.
	For the three months ended March 31, 2014, the following related party stock-based compensation was recorded:
	Related Party	Position	Amount
	Dr. Dorothy Bray*	CEO	$	750,549
	Robert Kane	CFO		268,548
	Chad S. Johnson, Esq.	COO and General Counsel		721,500
	Mario Lap*	Director		744,308
			$	2,484,905
	*Including stock compensation in companies beneficially owned by the related parties.
	See Note 7 for details of stock issuances to director and officers for services rendered.
	During the three months ended March 31, 2014, a stockholder of the Company, Intrinsic Venture Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Note Amount	Issue Date
	$13,500	February 7, 2014 (non-cash)
	New loans from Intrinsic Venture Corp. included in notes payable to stockholders were $13,500 during the three months ended March 31, 2014.  Notes payable to Intrinsic Venture Corp. totaled $1,815,267 at March 31, 2014 and $1,831,969 at December 31, 2013.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	6.  NOTES PAYABLE
	As of March 31, 2014, a total of $2,086,186 (December 31, 2013: $2,102,186) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on April 1, 2014 through March 8, 2015.   A stockholder, to whom $1,815,267 (December 31, 2013: $1,811,767) in promissory notes are due, also performs business and accounting services for the Company on a month-to-month basis.  A total of $100,717 (December 31, 2013: $120,217) is due to a stockholder under promissory notes that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 17 through September 30, 2014.

Equity_Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
EQUITY TRANSACTIONS	'
	7.  EQUITY TRANSACTIONS
	The Company is authorized to issue 850,000,000 shares of common stock with a par value of $0.001 per share.  These shares have full voting rights.  There were 836,783,906 shares issued and outstanding as of March 31, 2014.
	The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share.  These shares have 10 votes per share.  There were 0 shares issued and outstanding as of March 31, 2014.
	The Company is also authorized to issue 1,000,000 shares of preferred stock, with a par value of $0.001 per share.  These shares have full voting rights of 1,000 votes per share.  There were 1,000,000 shares issued and outstanding as of March 31, 2014.
	On February 9, 2012, the Company established a 2012 Equity Compensation Plan that authorizes the Company to issue up to 50,000,000 common shares to staff or consultants for services to or on behalf of the Company.  The Company filed a Registration Statement Form S-8 with the U.S. Securities and Exchange Commission on February 14, 2012, file no. 333-179501, to register the shares covered under the plan.  As of March 31, 2014, the Company has issued 48,250,000 common shares compensation under the plan.
	During the three months ended March 31, 2014, the Company issued the following common stock:
	On January 3, 2014, the Company issued 10,000,000 common shares for settlement of $10,000 of stockholder debt, for a loss on settlement of $590,000, assigned from the stockholder notes payable originating on May 17, 2013.
	On January 6, 2014, the Company issued 10,000,000 common shares for settlement of $10,000 of stockholder debt, for a loss on settlement of $681,000, assigned from the stockholder notes payable originating on January 30, 2012.
	On January 7, 2014, the Company issued 9,500,000 common shares for settlement of $9,500 of stockholder debt, for a loss on settlement of $845,500, assigned from the stockholder notes payable originating on May 17, 2013.
	On January 15, 2014, the Company issued 2,000,000 S-8 registered free trading shares of common stock with a fair market value of $192,400 or $0.0962 per share to each of Dr. Dorothy Bray, CEO, Chad S. Johnson, COO and General Counsel, and Mario Lap, Director for bonuses under prior management agreements.
	On January 15, 2014, the Company issued 5,500,000 Rule 144 restricted shares of common stock with a fair market value of $529,100 or $0.0962 per share to each of Dr. Dorothy Bray, CEO, Chad S. Johnson, COO and General Counsel, and Mario Lap, Director for bonuses under prior management agreements.
	On January 15, 2014, the Company issued 2,500,000 Rule 144 restricted shares of common stock with a fair market value of $240,500 or $0.0962 per share to Robert Kane, CFO as a bonus under prior management agreement.
	On January 24, 2014, the Company issued 5,000,000 S-8 registered free-trading shares of common stock to a marketing consultant for services rendered under a December 18, 2013 consulting agreement.  The fair market value of the shares was $0.0312 per share or $156,000.
	On February 13, 2014, the Company entered into a partnership agreement with Michigan Green Technologies, LLC.  Under the agreement, the Company participates in 20% of all net profit of the operating entity.  In addition, the Company is working with its partner to active lobbying for the legalization of hemp and cannabis in Michigan which will lead to additional business opportunities for the Company through its partnership.
	On March 8, 2014, the Company issued a private placement offering for 4,000,000 units at $0.25 per unit. Each unit is comprised of one share of common stock and one non-transferable warrant with each one warrant to purchase one share of the Company’s common stock at an exercise price of $0.50. The warrants shall expire 2 years from the date of issuance of the warrant certificate (collectively “Offered Units”).  The Company received $940,000 under the offering for three months ended March 31, 2014.  3,760,000 units subscribed were recorded as issued and outstanding as of March 31, 2014 with the remaining 240,000 units issued on June 2, 2014 for $60,000 in offering proceeds received in the subsequent period ended June 2, 2014. The weighted-average fair value of warrants and related warrant expense was estimated to be $97,894 for the three months ended March 31, 2014 using the Black-Scholes option valuation model.
	On March 31, 2014, the Company entered into a Debt Extension Agreement with Intrinsic Venture Corp., to avoid default on approximately $1.8 million in promissory notes due, to extend due dates by 12 months on all promissory notes including those becoming due during fiscal 2014.  The Company agreed to issue 5,000,000 rule 144 restricted shares of common stock with a fair market value of $0.1666 per share or $833,000 as consideration for the extensions on the aforementioned promissory notes.
	Stock Options:
	The following options were issued to Robert Kane, CFO and Director for services rendered under a September 16, 2011 agreement:
	(i)	the option to purchase 100,000 common shares at ten cents ($0.10) per share;
	(ii)	the option to purchase 100,000 common shares at ten cents ($0.20) per share;
	(iii)	the option to purchase 500,000 common shares at ten cents ($0.35) per share; and
	(iv)	the option to purchase 1,000,000 common shares at ten cents ($0.50) per share.
	A summary of the status of the Company’s option grants as of March 31, 2014 and the changes during the period then ended is presented below:
			Shares			Weighted-Average
						Exercise Price
	Outstanding December 31, 2013			1,700,000		$	0.41
	Granted			–			–
	Exercised			–			–
	Expired			–			–
	Outstanding March 31, 2014			1,700,000		$	0.41
	Options exercisable at March 31, 2014			1,700,000		$	0.41
	These options expire on the date of termination of the management agreement and services thereunder with Robert Kane. The weighted average fair value at date of grant for options during three months ended March 31, 2014 was estimated using the Black-Scholes option valuation model with the following:
	Average expected life in years			2
	Average risk-free interest rate			2	%
	Average volatility			75	%
	Dividend yield			0	%

Equipment

Equipment	3 Months Ended
	Mar. 31, 2014
Equipment [Abstract]	'
EQUIPMENT	'
	8.  EQUIPMENT
				Accumulated		Net Book Value		Net Book Value
						March 31,		December 31,
		Cost		Depreciation		2014		2013
	Equipment	$	3,000	$	3,000	$	-	$	-
	Software		5,000		4,109		891		1,516
	Computers		5,716		5,716		-		-
		$	13,716	$	12,825	$	891	$	16,412
	All equipment is stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, and 5 years for equipment and laboratory equipment.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
INTANGIBLE ASSETS	'
	9. INTANGIBLE ASSETS
		March 31,			December 31,
		2014			2013
	Intellectual assets, primarily intellectual property	$	445,299		$	445,299
	Less accumulated amortization		(259,733	)		(238,590	)
		$	185,566		$	206,709
	Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for intellectual assets).

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	10.  SUBSEQUENT EVENTS
	On April 28, 2014, the Company filed a Form S-8 (file no. 333-195510) registering 6,500,000 common shares under a 2014 Stock Compensation Plan.
	Subsequent to the three months ended March 31, 2014, the Company issued the following stock:
	On April 26, 2014, the Company issued 1,300,000 S-8 registered free-trading shares of common stock with a fair market value of $132,600 or $0.102 per share to a consultant for services rendered under a 6-month consulting agreement.
	On April 30, 2014, the Company issued 1,500,000 S-8 registered free-trading shares of common stock with a fair market value of $126,600 or $0.0844 per share to each of Dorothy Bray, Chad S. Johnson, Robert Kane, and Mario Lap directors and officers of the Company for bonuses under prior management agreements.
	On May 20, 2014, the Company entered into a one-year Scientific Advisor Consulting Agreement with Robert Melamede, Ph.D.  Under the Agreement, Dr. Melamede will be compensated 250,000 Rule 144 restricted common shares with a fair market value of $17,500.  In addition, he will be paid $25,000 owed for accrued management fees within 30 days and issued 6,967,085 Rule 144 restricted common shares for settlement of $387,696 in accrued management fees and $100,000 in bonuses.
	On May 20, 2014, Robert Melamede, Ph.D. resigned as Director, Chairman of the Board of Directors, President, and director and officer positions in the Company’s subsidiaries.  Dr. Dorothy Bray assumed the role of interim President and was formally appointed as President and Chairperson of the Board of Directors on May 31, 2014.  Dr. Melamede will continue as a key scientific advisor to the Company and retain the title “Cannabis Science President Emeritus”.
	On May 20, 2014, Bogat Family Trust (Raymond Dabney, Trustee) (“Bogat”) and Robert Melamede, Ph.D. (Melamede) entered into a Stock Purchase Agreement whereby Bogat purchased 500,000 Series A preferred shares from Melamede for par value of $0.001 per share, or $500.  Upon completion of the transaction, Bogot owned 1,000,000 shares of Series A preferred stock representing all of the issued and outstanding Series A preferred shares.   As of June 2, 2014 filing date, Bogat has approximately 57% cumulative voting control of the Company.
	On June 2, 2014, the Company issued the remaining 240,000 common shares for units subscribed under its March 8, 2014 offering were issued to investors.  See Note 7.
	Common shares reconciliation table:
	Issued and outstanding as of March 31, 2014	836,783,906
	Pending and subsequent event issuances	7,540,000
	Unissued and outstanding as of June 2, 2014	844,323,906

Recovered_Sheet1

Summary Of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	B.  Basis of Presentation
	These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars.  The Company’s fiscal year end is December 31.
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP").  These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2013 audited financial statements of Cannabis Science, Inc. (the “Company”).  All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended March 31, 2014 and 2013.  It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2013 included in our Form 10-K, filed with the Securities Exchange Commission on April 23, 2013. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that can be expected for the year ending December 31, 2014.
	The operating results of GGECO University, Inc. (“GGECO”), acquired on February 9, 2012, for the period February 10, 2012 through December 31, 2013 were consolidated with the consolidated financial statements of the Company for the year ended December 31, 2013.  The s-type corporation of GGECO was dissolved in 2012 and all operations combined into the Company’s.  An independent valuation firm determined the intangibles acquired in GGECO to be $192,119 consisting of $150,000 for educational materials, $20,000 for the trade name, and $22,119 for the workforce.  The total purchase price of $450,132, including acquired net liabilities, audit and valuation costs was recorded.  A total of $44,274 in unimpaired goodwill remains at March 31, 2014.
	The operating results of Cannabis Consulting, Inc. (“CCI”), acquired on March 21, 2012, for the period March 21, 2012 through December 31, 2013 and January 1, 2014 through March 31, 2014 were consolidated with the consolidated financial statements of the Company for the three months ended March 31, 2014.  The s-type corporation of CCI was dissolved in 2012 and all operations combined into the Company’s.  The Company has allocated $125,000 of the purchase price to intangibles based on an internal valuation in addition to $22,000 of goodwill.  No impairment in the fair market value of CCI was determined at March 31, 2014.
	On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations.  No business or operating activities have commenced in the subsidiaries as of March 31, 2014.
Use of Estimates	'
	C.  Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
Basic and Diluted Net Income (Loss) Per Share	'
	D.  Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share.  Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.  For the three months ended March 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
Cash and Cash Equivalents	'
	E.  Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Long-Lived Assets & Impairment on Oil Lease Investments	'
	F. Long-Lived Assets & Impairment on Oil Lease Investments
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used.  ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts.  In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets.  Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
Inventory	'
	G. Inventory
	Inventories are stated at the lower of cost or market, using the average cost method. Cost includes materials related to the purchase and production of inventories. We regularly review inventory quantities on hand, future purchase commitments with our suppliers, and the estimated utility of our inventory. If our review indicates a reduction in utility below carrying value, we reduce our inventory to a new cost basis through a charge to cost of revenue.
Fair Value Measurements	'
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments.  The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4).  The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments.  None of these instruments are held for trading purposes.
Goodwill and Intangible Assets	'
	I. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. The Company did not identify any impairment on its outstanding goodwill from its most recent testing, which was performed as of October 1, 2013. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as customer lists, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight line method over estimated useful lives of five years.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired.  If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action.  If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
	The Company did not record an impairment loss on goodwill for the quarter ended March 31, 2014 and did not record an impairment loss on goodwill for 2013 that was included in operating expenses and resulting net operating loss.
Research and Development Expenses	'
	J. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Income Taxes	'
	K. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards.  Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards.  A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns
	In February 2009, the Company filed appropriate federal tax returns for the years ending December 31, 2003 through 2007 and may be subject to failure to file penalties.  For the years ending December 31, 2008 through December 31, 2013, the Company has not filed any federal tax returns.  The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position.  No provisions have been made in the financial statements for such penalties, if any.
	The Company is working with its accountants to prepare and file overdue federal tax returns for 2008 through 2013, which are anticipated to be completed and filed by the end of fiscal 2014.
Marketable Securities	'
	L. Marketable Securities
	Under ASC Topic 210; Rule 5-02.2, ‘‘Marketable Securities’’, the Company is required to measure all marketable securities at their carrying value while recognizing unrealized gains and losses as of the reporting date.
Stock-Based Compensation	'
	M. Stock-Based Compensation
	Under  ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations.  The Company has adopted ASC Topic 718 (SFAS 123R) as of January 1, 2006 and recognizes stock-based compensation expense using the modified prospective method.
Revenue Recognition	'
	N.  Revenue Recognition
	Revenue is recognized at the time the educational materials or online seminars are provided and billed to the customer and collection of such fee is reasonably assured.  License fees and joint-venture profit sharing when evidenced by executed agreements, and other fees are recognized when earned and collection is reasonably assured.
Development Stage Enterprise	'
	O.  Development Stage Enterprise
	The Company is no longer in the development stage.  The Company has filed patents and is actively working on formulations for cannabinoid-based drug development, filing INDs, and commencing drug trials for FDA approved medicine.  The Company’s businesses of GGECO and CCI acquired during 2012 are continuing and the Company’s other activities under license agreements with Apothecary has completed over a year of active business and development with expanding operations along with associated business. The Company continues to work to prosecute patents and develop its two key drugs, namely CS-TATI-1 targeting both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies and CS-S/BCC-1 targeting basal and squamous cell carcinomas, along with its cannabinol (CBN) patent. In addition, the Company is working to progress licensing activity with Apothecary along with MOU activity with Prescription Vending Machines, Inc., a wholly-owned subsidiary of Medbox, Inc.
Recent Accounting Pronouncements	'
	P. Recent Accounting Pronouncements
	During the three months ended March 31, 2014 and through June 2, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company.  Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
Reclassifications	'
	Q. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Recovered_Sheet2

Fair Value Measurements And Disclosures (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements and Disclosures [Abstract]	'
Schedule of company's assets at fair value	'
	31-Dec-13
		Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	225,000	$	-	$	-	$	225,000
	Intangibles from acquisitions, GGECO and CCI net of accumulated amortization		-		-		237,480		237,480
	Total assets as of December 31, 2013	$	225,000	$	-	$	237,480	$	462,480
	31-Mar-14
		Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	204,000	$	-	$	-	$	204,000
	Intangibles from GGECO and CCI acquisitions, net of accumulated amortization		-		-		237,480		237,480
	Total assets as of March 31, 2014	$	204,000	$	-	$	237,480	$	441,480

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Schedule of stock based compensation with related party	'
	Related Party	Position	Amount
	Dr. Dorothy Bray*	CEO	$	750,549
	Robert Kane	CFO		268,548
	Chad S. Johnson, Esq.	COO and General Counsel		721,500
	Mario Lap*	Director		744,308
			$	2,484,905
	*Including stock compensation in companies beneficially owned by the related parties.
Schedule of loans received from stockholders	'
	Note Amount	Issue Date
	$13,500	February 7, 2014 (non-cash)

Equity_Transactions_Tables

Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Equity Transactions Tables	'
Schedule of stock options outstanding	'
		Shares			Weighted-Average
					Exercise Price
	Outstanding December 31, 2013		1,700,000		$	0.41
	Granted		–			–
	Exercised		–			–
	Expired		–			–
	Outstanding March 31, 2014		1,700,000		$	0.41
	Options exercisable at March 31, 2014		1,700,000		$	0.41
Schedule of fair value assumptions of stock options	'
	Average expected life in years		2
	Average risk-free interest rate		2	%
	Average volatility		75	%
	Dividend yield		0	%

Equipment_Tables

Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Equipment [Abstract]	'
Schedule Of Equipment	'
				Accumulated		Net Book Value		Net Book Value
						March 31,		December 31,
		Cost		Depreciation		2014		2013
	Equipment	$	3,000	$	3,000	$	-	$	-
	Software		5,000		4,109		891		1,516
	Computers		5,716		5,716		-		-
		$	13,716	$	12,825	$	891	$	16,412

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Schedule Of Intangible Assets	'
		March 31,			December 31,
		2014			2013
	Intellectual assets, primarily intellectual property	$	445,299		$	445,299
	Less accumulated amortization		(259,733	)		(238,590	)
		$	185,566		$	206,709

Subsequent_Events_Tables

Subsequent Events (Tables)	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Schedule Of Common Shares Reconciliation	'
	Common shares reconciliation table:
	Issued and outstanding as of March 31, 2014	836,783,906
	Pending and subsequent event issuances	7,540,000
	Unissued and outstanding as of June 2, 2014	844,323,906

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Feb. 09, 2012	Feb. 09, 2012	Feb. 09, 2012	Feb. 09, 2012	Mar. 21, 2012
				GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	Cannabis Consulting, Inc
						Education Materials	Trade Name	Workforce
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business acquisition purchase price	'	'	'	'	$450,132	'	'	'	'
Value of intangibles acquired	'	'	'	'	192,119	150,000	20,000	22,119	125,000
Value of goodwiil	66,274	'	66,274	44,274	'	'	'	'	22,000
Impairment loss on goodwill	'	'	'	'	'	'	'	'	'

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Going Concern (Textual)	'	'	'	'	'
Accumulated deficit	($98,335,789)	'	($92,508,542)	'	'
Stockholders' deficit	-2,555,434	'	-3,518,819	-2,168,965	-2,230,401
Proceeds from sale of common stock	$940,000	'	'	'	'

Marketable_Securities_Details

Marketable Securities (Details) (Endocan Corporation, USD $)	3 Months Ended
	Mar. 31, 2014
Endocan Corporation	'
Common stock issued in connection with joint ventures, Shares	7,500,000
Fair market value of shares acquired	$539,250

Fair_Value_Measurements_And_Di1

Fair Value Measurements And Disclosures (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	$204,000	$225,000
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	237,480	237,480
Total assets	441,480	462,480
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	204,000	225,000
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	'	'
Total assets	204,000	225,000
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	'	'
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	'	'
Total assets	'	'
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	'	'
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	237,480	237,480
Total assets	$237,480	$237,480

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Stock based compensation expense	$2,484,905
Dr.Dorothy Bray	'
Stock based compensation expense	750,549
Robert Kane	'
Stock based compensation expense	268,548
Chad S.Johnson, Esq.	'
Stock based compensation expense	721,500
Mario Lap	'
Stock based compensation expense	$744,308

Related_Party_Transactions_Det1

Related Party Transactions (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Debt Instrument [Line Items]	'
Debt instrument face amount	$1,800,000
Intrinsic Venture Corp. | Notes Payable - February 7, 2014 (non-cash) [Member]	'
Debt Instrument [Line Items]	'
Debt instrument face amount	$13,500
Debt instrument issue date	7-Feb-14

Related_Party_Transactions_Det2

Related Party Transactions (Details Textual) (USD $)	0 Months Ended		3 Months Ended
	Feb. 08, 2013	Dec. 12, 2012	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Advances from related parties	'	'	$191,344	'	$191,344
Common shares held in X-Change Corporation	2,500,000	5,000,000	7,500,000	'	'
Sale of Stock, Price Per Share	$0.10	$0.03	$0.07	'	'
Loss on marketable securitites	'	'	314,250	-149,750	'
Fair Market Value	262,250	150,000	539,250	'	'
Common shares issued and outstanding percentage	'	'	8.60%	'	'
Debt instrument face amount	'	'	1,800,000	'	'
Notes Payable	'	'	1,815,267	'	1,811,767
Bogat Family Trust | Loans Payable	'	'	'	'	'
Advances from related parties	'	'	191,344	'	191,344
Raymond Dabney | Loans Payable	'	'	'	'	'
Advances from related parties	'	'	0	'	6,166
Intrinsic Capital Corp.	'	'	'	'	'
Debt instrument face amount	'	'	$13,500	'	$1,250

Notes_Payable_Details

Notes Payable (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Notes Payable [Abstract]	'	'
Debt instrument description	'As at March 31, 2014, a total of $2,086,186 (December 31, 2013: $2,102,186) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on April 1, 2014 through March 8, 2015.	'
Notes payable to stockholders	$2,086,186	$2,102,186
Notes Payable	1,815,267	1,811,767
Debt instrument description one	'A total of $100,717 (December 31, 2013: $120,217) is due to a stockholder under promissory notes that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 17 through September 30, 2014.	'
Promissory notes payable to stockholders	$100,717	$120,217

Equity_Transactions_Schedule_O

Equity Transactions (Schedule Of Stock Options Outstanding) (Details) (Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option [Member]	'	'	'
Shares	'	'	'
Outstanding December 31, 2013	1,700,000	'	1,700,000
Granted	'	'	'
Exercised	'	'	'
Expired	'	'	'
Outstanding March 31, 2014	1,700,000	'	1,700,000
Options exercisable at March 31, 2014	1,700,000	1,700,000	'
Weighted Average Exercise Price	'	'	'
Outstanding December 31, 2013	$0.41	'	$0.41
Granted	'	'	'
Exercised	'	'	'
Expired	'	'	'
Outstanding March 31, 2014	$0.41	'	$0.41
Options exercisable at March 31, 2014	$0.41	$0.41	'

Equity_Transactions_Schedule_O1

Equity Transactions (Schedule Of Fair Value Assumptions Of Stock Options) (Details) (Stock Option [Member])	3 Months Ended
	Mar. 31, 2014
Stock Option [Member]	'
Fair value of Stock Options - Black Scholes Options Valuation Model	'
Average expected life in years	'2 years
Average risk-free interest rate	2.00%
Average volatility	75.00%
Dividend yield	0.00%

Equity_Transactions_Narrative_

Equity Transactions (Narrative) (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

2 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

Feb. 13, 2014

Feb. 09, 2012

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 08, 2013

Dec. 12, 2012

Apr. 26, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 08, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 02, 2014

Mar. 31, 2014

Jan. 24, 2014

Mar. 31, 2014

Jan. 15, 2014

Jan. 15, 2014

Jan. 15, 2014

Jan. 15, 2014

Subsequent Event [Member]

January 3, 2014 [Member]

January 6, 2014 [Member]

January 7, 2014 [Member]

Common Class A [Member]

Common Class A [Member]

Private Placement [Member]

Stock option

Stock option 1

Stock option 2

Stock option 3

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Subsequent Event [Member]

Subsequent Event [Member]

Consultant for business development services

Common Class A [Member]

Mario Lap

Chad S. Johnson, Esq, COO

Dr. Dorothy Bray

Robert Kane

Common Stock, Shares Authorized

'

'

850,000,000

'

850,000,000

'

'

'

'

'

'

'

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share

'

'

$0.00

'

$0.00

'

'

'

$0.10

'

'

'

$0.00

$0.00

$0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

836,783,906

'

770,523,906

663,790,573

'

'

1,300,000

'

'

'

0

0

'

'

'

'

'

'

'

'

'

240,000

836,783,906

'

'

'

'

'

'

Common Stock, Shares, Outstanding

'

'

836,783,906

'

770,523,906

'

'

'

'

'

'

'

0

0

'

'

'

'

'

836,783,906

770,523,906

663,790,573

305,420,574

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

1,000,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Voting Rights

'

'

'1,000 votes per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 votes per share

'

'

'

'

Preferred Stock, Shares Issued

'

'

1,000,000

'

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

1,000,000

'

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued to staff or consultants for services

'

50,000,000

48,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

28,000,000

57,900,000

171,669,999

'

'

'

'

'

2,000,000

2,000,000

2,000,000

'

Common stock issued for debt settlements, Shares

'

'

'

'

'

'

'

'

'

10,000,000

10,000,000

9,500,000

'

'

'

'

'

'

'

'

'

155,700,000

'

'

'

5,000,000

'

'

'

'

'

Debt settlement amount

'

'

$29,500

$13,500

'

'

'

'

'

$10,000

$10,000

$9,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on settlement of debt

'

'

-2,116,500

-1,092,150

'

'

'

'

'

590,000

681,000

845,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services, Amount

'

'

2,871,632

'

1,009,630

1,147,425

'

'

'

'

'

'

'

'

'

'

'

'

'

28,000

57,900

171,670

'

'

'

156,000

'

192,400

192,400

192,400

'

Sale of Stock, Price Per Share

'

'

$0.07

'

'

'

$0.10

$0.03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.03

'

'

'

'

'

Common shares issuable from option issued to the company's V.P

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

100,000

500,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options issued to the Company's V.P

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

$0.20

$0.35

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares of common stock, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,500,000

5,500,000

5,500,000

2,500,000

Restricted shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

529,100

529,100

529,100

240,500

Restricted common stock per share value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.17

'

'

'

'

'

'

'

$0.10

$0.10

$0.10

$0.10

Net profit percentage

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Each unit is comprised of one share of common stock and one non-transferable warrant with each one warrant to purchase one share of the Company’s common stock at an exercise price of $0.50.

Net offering proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

Amount received under offering

'

'

940,000

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,760

833

'

'

'

'

'

'

'

'

'

'

Warrant expense

'

'

97,894

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares subscribed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,760,000

833,333

'

'

'

'

'

'

'

'

'

'

Debt instrument face amount

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for extension of debt

'

'

$833,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for debt extension, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

Equipment_Details

Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Cost	$13,716	'
Accumulated depreciation	12,825	12,200
Net book value	891	1,516
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	3,000	'
Accumulated depreciation	3,000	'
Net book value	'	'
Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	5,000	'
Accumulated depreciation	4,109	'
Net book value	891	1,516
Computers [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	5,716	'
Accumulated depreciation	5,716	'
Net book value	'	'

Equipment_Details_Textual

Equipment (Details Textual)	3 Months Ended
	Mar. 31, 2014
Computers [Member]	'
Useful life of Equipment	'2 years
Software [Member]	'
Useful life of Equipment	'2 years
Equipment [Member]	'
Useful life of Equipment	'5 years
Laboratory Equipment [Member]	'
Useful life of Equipment	'5 years

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Intangible Assets [Abstract]	'	'
Intellectual assets, primarily intellectual property	$445,299	$445,299
Less accumulated amortization	-259,733	-238,590
Intangible assets, net	$185,566	$206,709

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (Intangible Assets)	3 Months Ended
	Mar. 31, 2014
Intangible Assets	'
Useful life of Intangible	'5 years

Subsequent_Events_Schedule_Of_

Subsequent Events (Schedule Of Common Shares Reconciliation) (Details) (Common Stock, Subsequent Event [Member])	2 Months Ended
	Jun. 02, 2014
Common Stock | Subsequent Event [Member]	'
Issued and outstanding as of March 31, 2014	836,783,906
Pending and subsequent event issuances	7,540,000
Unissued and outstanding as of June 2, 2014	844,323,906

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 08, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jan. 24, 2014

Apr. 26, 2014

Jun. 02, 2014

Mar. 31, 2014

Apr. 28, 2014

20-May-14

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

20-May-14

Private Placement [Member]

Common Stock

Common Stock

Common Stock

Common Stock

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Consultant For Business Development Services

Common Stock

Common Stock

Stock Compensation Plan [Member]

Scientific Advisor Consulting Agreement [Member]

Dr.Dorothy Bray

Mario Lap

Chad S.Johnson, Esq.

Robert Kane (Member)

Raymond Dabney

Series A Preferred Stock [Member]

Common stock, shares authorized

850,000,000

850,000,000

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

'

'

Common stock, par value

$0.00

$0.00

'

$0.25

'

'

'

'

$0.10

'

'

'

'

$0.08

$0.08

$0.08

$0.08

'

Common stock, shares issued

836,783,906

770,523,906

663,790,573

'

'

'

'

'

1,300,000

240,000

836,783,906

'

'

1,500,000

1,500,000

1,500,000

1,500,000

'

Common stock value

$836,784

$770,524

'

'

'

'

'

'

$132,600

'

'

'

'

$126,600

$126,600

$126,600

$126,600

'

Common stock issued for services, Amount

2,871,632

1,009,630

1,147,425

'

28,000

57,900

171,670

156,000

'

'

'

'

17,500

'

'

'

'

'

Shares issued for services

'

'

'

4,000,000

28,000,000

57,900,000

171,669,999

'

'

'

'

'

250,000

'

'

'

'

'

Accrued management fees

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

Accrued Bonuses

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

common shares for settlement, Value

'

'

'

'

'

'

'

'

'

'

'

'

387,696

'

'

'

'

'

common shares for settlement, Shares

'

'

'

'

'

'

'

'

'

'

'

'

6,967,085

'

'

'

'

'

Preferred stock, shares issued

1,000,000

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

Preferred stock, shares issued, Amount

$1,000

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$500

Preferred stock, par value

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

Number of preferred shares owned

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Preferred stock, Voting rights

'1,000 votes per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'As of June 2, 2014 filing date, Bogat has approximately 57% cumulative voting control of the Company.